Section 4: Clinical Pharmacy Services

4CPS-139

STUDY ASSESSING THE USE OF HIGH-COST OFF-LABEL DRUGS IN THE TREATMENT OF ATOPIC DERMATITIS

4CPS-134

EVOLUTION AND ANALYSIS OF SPENDING ON BIOLOGICAL MEDICATION IN PSORASIS

4CPS-128

EFFECTIVENESS OF ABIRATERONE ACETATE AND ENZALUTAMIDE IN METASTATIC CASTRATIONRESISTANT PROSTATE CANCER

4CPS-125

OF ERIBULIN IN LOCALLY ADVANCED OR METASTATIC BREAST CANCER

4CPS-121

IMPACT OF PHARMACEUTICAL CONSULTATIONS FOR NEW ORAL ONCOLOGY AGENTS

4CPS-120

CASE REPORT: USE OF VISMODEGIB IN A PATIENT WITH GORLIN GOLTZ SYNDROME

4CPS-113

EXPERIENCE WITH BRAF AND MEK INHIBITORS IN THE TREATMENT OF METASTASIC MELANOMA IN A THIRD-LEVEL UNIVERSITY HOSPITAL

4CPS-111

EFECTIVENESS AND COST OF ABIRATERONE AND ENZALUTAMIDE IN PROSTATE CANCER

4CPS-107

AN ESTIMATE OF AVOIDED COSTS FOR DRUGS IN PATIENTS INCLUDED IN NON-SMALL LUNG CANCER CLINICAL TRIALS

4CPS-106

IMPACT OF ONCOLOGICAL CLINICAL TRIALS IN A HOSPITAL PHARMACY

4CPS-102

ANALYSIS OF OFF-LABEL USE IN ONCOHAEMATOLOGY

4CPS-101

CHEMOTHERAPY DOSE ADJUSTMENT IN RELATION TO PATIENTS’ NUTRITIONAL STATUS

4CPS-099

NIVOLUMAB: CLINICAL EXPERIENCE IN A TERTIARY HOSPITAL

4CPS-098

USE OF PALIVIZUMAB IN THE IMMUNOPROFILAXIS OF RESPIRATORY SYNCYTIAL VIRUS

4CPS-096

EFFECTIVENESS, SAFETY AND POTENTIAL INTERACTIONS OF ELBASVIR/GRAZOPREVIR FOR CHRONIC HEPATITIS C INFECTION

Pages